Titre :

Adjustable continence therapy balloons in women: Evolution of efficacy within the 24 months following implantation.

Auteur(s) :

Guiffart, P [Auteur]
Reix, B [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Martin-Malburet, A [Auteur]
Marcelli, F [Auteur]
518922|||Gamétogenèse et Qualité du Gamète - ULR 4308 [GQG] (OLD)
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Biardeau, Xavier [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]

Titre de la revue :

Progrès en Urologie

Nom court de la revue :

Prog. Urol.

Numéro :

28

Pagination :

927-934

Date de publication :

2018-12

ISSN :

1166-7087

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

PURPOSE: To analyze the functional outcomes over time of ACT balloon in women with stress urinary incontinence (SUI) secondary to intrinsic sphincter deficiency (ISD). METHOD: All patients with SUI secondary to ISD who ...
Lire la suite >PURPOSE: To analyze the functional outcomes over time of ACT balloon in women with stress urinary incontinence (SUI) secondary to intrinsic sphincter deficiency (ISD). METHOD: All patients with SUI secondary to ISD who underwent bilateral ACT balloon implantation between September 2008 and November 2015 and regularly monitored for a period of at least 24 months were eligible. The results were studied at 6, 12 and 24 months. Efficacy was defined as: Success - maximum 1 safety pad per day and visual analogue scale (VAS) rating>/=9/10. Improvement - decrease in the number of pads used per day and VAS>/=5/10. Failure - increase or stability of the number of pads used per day and/or VAS<5/10. Failure was considered as primary when it occurred without any success or improvement. It was considered as secondary when it occurred after an initial period of success or improvement. RESULTS: 18 patients were monitored during 24 months. The success rate was respectively 17 %, 33 % and 33 % at 6, 12 and 24 months of follow-up. The improvement rate was respectively 61 %, 39 % and 17 % at 6, 12 and 24 months of follow-up. The primary failure rate was 22 %. The secondary failure rate was 6 % at 12 months and 33 % at 24 months of follow-up. CONCLUSION: ACT balloon efficacy tends to decrease with time requiring a long-term follow-up of implanted patients. LEVEL OF EVIDENCE: 4.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Équipe(s) de recherche :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Date de dépôt :

2019-03-01T14:07:55Z
2024-04-05T08:59:44Z